Cholesterol efflux capacity is an independent predictor of all-cause and cardiovascular mortality in patients with coronary artery disease: A prospective cohort study

Reiner, 2011, ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis Society (EAS), Eur. Heart J., 32, 1769, 10.1093/eurheartj/ehr158 Silbernagel, 2013, High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality, Eur. Heart J., 34, 3563, 10.1093/eurheartj/eht343 Franceschini, 2001, Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease, Am. J. Cardiol., 88, 9, 10.1016/S0002-9149(01)02146-4 Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur. Heart J., 32, 1345, 10.1093/eurheartj/ehr112 Collins, 2004, Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions, Lancet, 363, 757, 10.1016/S0140-6736(04)15690-0 Reiner, 2013, Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update, Nutr. Metab. Cardiovasc. Dis. NMCD, 23, 799, 10.1016/j.numecd.2013.05.002 Briel, 2009, Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis, BMJ Clin. Res. Ed., 338, b92, 10.1136/bmj.b92 Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis, N. Engl. J. Med., 356, 1304, 10.1056/NEJMoa070635 Schwartz, 2012, Effects of dalcetrapib in patients with a recent acute coronary syndrome, N. Engl. J. Med., 367, 2089, 10.1056/NEJMoa1206797 Rader, 2014, HDL and cardiovascular disease, Lancet, 384, 618, 10.1016/S0140-6736(14)61217-4 Rosenson, 2012, Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport, Circulation, 125, 1905, 10.1161/CIRCULATIONAHA.111.066589 Rader, 2009, The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis, J. Lipid Res., 50, S189, 10.1194/jlr.R800088-JLR200 Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis, N. Engl. J. Med., 364, 127, 10.1056/NEJMoa1001689 Scharnagl, 2014, Decreased cholesterol efflux capacity in patients with low cholesteryl ester transfer protein plasma levels, Eur. J. Clin. Invest., 44, 395, 10.1111/eci.12248 Li, 2013, Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks, Arterioscler. Thromb. Vasc. Biol., 33, 1696, 10.1161/ATVBAHA.113.301373 Rohatgi, 2014, HDL cholesterol efflux capacity and incident cardiovascular events, N. Engl. J. Med., 371, 2383, 10.1056/NEJMoa1409065 Saleheen, 2015, Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study, Lancet. Diabetes Endocrinol., 3, 507, 10.1016/S2213-8587(15)00126-6 Ding, 2014, Serum lipids, apolipoproteins, and mortality among coronary artery disease patients, BioMed Res. Int., 2014, 10.1155/2014/709756 Ding, 2014, Hyperglycemia and mortality among patients with coronary artery disease, Diabetes Care, 37, 546, 10.2337/dc13-1387 Gibbons, 1999, J. Am. Coll. Cardiol., 33, 2092, 10.1016/S0735-1097(99)00150-3 Braunwald, 2000, J. Am. Coll. Cardiol., 36, 970, 10.1016/S0735-1097(00)00889-5 Li, 2013, The prevalence and awareness of cardiometabolic risk factors in Southern Chinese population with coronary artery disease, Scientific World J., 2013, 416192, 10.1155/2013/416192 Patel, 2011, The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease, J. Am. Coll. Cardiol., 58, 2068, 10.1016/j.jacc.2011.08.030 Omland, 2009, A sensitive cardiac troponin T assay in stable coronary artery disease, N. Engl. J. Med., 361, 2538, 10.1056/NEJMoa0805299 Pencina, 2008, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Statistics Med., 27, 157, 10.1002/sim.2929 Pickering, 2012, New metrics for assessing diagnostic potential of candidate biomarkers, Clin. J. Am. Soc. Nephrol. CJASN, 7, 1355, 10.2215/CJN.09590911 Feig, 2008, Atheroprotective effects of HDL: beyond reverse cholesterol transport, Curr. Drug Targets, 9, 196, 10.2174/138945008783755557 Navab, 2011, HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms, nature reviews, Cardiology, 8, 222 deGoma, 2008, Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches, J. Am. Coll. Cardiol., 51, 2199, 10.1016/j.jacc.2008.03.016 Arsenault, 2012, HDL cholesterol is not HDL–don't judge the book by its cover, Nat. Rev. Cardiol., 9, 557, 10.1038/nrcardio.2012.127 Doonan, 2014, Cholesterol efflux capacity, carotid atherosclerosis, and cerebrovascular symptomatology, Arterioscler. Thromb. Vasc. Biol., 34, 921, 10.1161/ATVBAHA.113.302590 Ritsch, 2015, HDL cholesterol efflux capacity and cardiovascular events, N. Engl. J. Med., 372, 1870 Oh, 2012, Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation, J. Biol. Chem., 287, 11629, 10.1074/jbc.M111.338673 Movva, 2008, Laboratory assessment of HDL heterogeneity and function, Clin. Chem., 54, 788, 10.1373/clinchem.2007.101923 Riwanto, 2013, Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling, Circulation, 127, 891, 10.1161/CIRCULATIONAHA.112.108753 Shao, 2006, Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I, J. Biol. Chem., 281, 9001, 10.1074/jbc.C600011200 Marsche, 2013, Inflammation alters HDL composition and function: implications for HDL-raising therapies, Pharmacol. Ther., 137, 341, 10.1016/j.pharmthera.2012.12.001 McGillicuddy, 2009, Inflammation impairs reverse cholesterol transport in vivo, Circulation, 119, 1135, 10.1161/CIRCULATIONAHA.108.810721 Ding, 2015, Serum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease, PLoS One, 10, e0120633, 10.1371/journal.pone.0120633 Su, 2013, Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease, Mediat. Inflamm., 2013, 726178, 10.1155/2013/726178 Gaudreault, 2013, Hyperglycemia impairs atherosclerosis regression in mice, Am. J. Pathol., 183, 1981, 10.1016/j.ajpath.2013.08.019 Moradi, 2014, Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients, Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc., 29, 1554 Rosenson, 2016, Dysfunctional HDL and atherosclerotic cardiovascular disease, Nat. Rev. Cardiol., 13, 48, 10.1038/nrcardio.2015.124 Gabay, 1999, Acute-phase proteins and other systemic responses to inflammation, N. Engl. J. Med., 340, 448, 10.1056/NEJM199902113400607 Clifton, 1985, Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction, J. Lipid Res., 26, 1389, 10.1016/S0022-2275(20)34244-9 Stonik, 2004, Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells, Biochem. Biophy. Res. Commun., 321, 936, 10.1016/j.bbrc.2004.07.052 van der Westhuyzen, 2005, Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I, J. Biol. Chem., 280, 35890, 10.1074/jbc.M505685200 Hafiane, 2014, High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes, Am. J. Cardiol., 113, 249, 10.1016/j.amjcard.2013.09.006